Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.

@article{Hylek2008DisparateSR,
  title={Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.},
  author={Elaine M. Hylek and Lars Frison and Lori Henault and Adrienne L Cupples},
  journal={Stroke},
  year={2008},
  volume={39 11},
  pages={3009-14}
}
BACKGROUND AND PURPOSE The rate of stroke among warfarin-treated patients in SPORTIF V was approximately half that of patients enrolled in SPORTIF III (1.16%/year versus 2.30%/year). SPORTIF III was an open-label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation. SPORTIF V was a double-blind trial performed in North America. The trial design was otherwise identical. We sought to determine if differences in baseline characteristics, use of potentially risk… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
SPORTIF III was an open - label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation .
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation : potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. BACKGROUND AND PURPOSE .
These findings suggest that the different event rates were not due to chance and provide potential insights into stroke risk among warfarin - treated patients with atrial fibrillation .
SPORTIF III was an open - label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation .
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation : potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. BACKGROUND AND PURPOSE .
These findings suggest that the different event rates were not due to chance and provide potential insights into stroke risk among warfarin - treated patients with atrial fibrillation .
SPORTIF III was an open - label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation .
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation : potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. BACKGROUND AND PURPOSE .
These findings suggest that the different event rates were not due to chance and provide potential insights into stroke risk among warfarin - treated patients with atrial fibrillation .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
We found that lower international normalized ratio variability , a higher proportion of prevalent warfarin use , lower systolic blood pressure , high - density lipoprotein , and a greater proportion of statin use among patients in SPORTIF V collectively conferred a lower risk of stroke .
We found that lower international normalized ratio variability , a higher proportion of prevalent warfarin use , lower systolic blood pressure , high - density lipoprotein , and a greater proportion of statin use among patients in SPORTIF V collectively conferred a lower risk of stroke .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
SPORTIF III was an open - label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation .
The rate of stroke among warfarin - treated patients in SPORTIF V was approximately half that of patients enrolled in SPORTIF III ( 1.16%/year versus 2.30%/year ) .
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation : potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. BACKGROUND AND PURPOSE .
These findings suggest that the different event rates were not due to chance and provide potential insights into stroke risk among warfarin - treated patients with atrial fibrillation .
We found that lower international normalized ratio variability , a higher proportion of prevalent warfarin use , lower systolic blood pressure , high - density lipoprotein , and a greater proportion of statin use among patients in SPORTIF V collectively conferred a lower risk of stroke .
Differences in blood pressure control , international normalized ratio variability , proportion of prevalent warfarin users , statin exposure , and high - density lipoprotein collectively conferred a lower risk of stroke to patients in SPORTIF V.
We sought to determine if differences in baseline characteristics , use of potentially risk - modifying medications , or anticoagulation control help to explain the lower risk of stroke among warfarin - treated patients in SPORTIF V. METHODS .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
These findings suggest that the different event rates were not due to chance and provide potential insights into stroke risk among warfarin - treated patients with atrial fibrillation .
Differences in blood pressure control , international normalized ratio variability , proportion of prevalent warfarin users , statin exposure , and high - density lipoprotein collectively conferred a lower risk of stroke to patients in SPORTIF V.
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation : potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. BACKGROUND AND PURPOSE .
We sought to determine if differences in baseline characteristics , use of potentially risk - modifying medications , or anticoagulation control help to explain the lower risk of stroke among warfarin - treated patients in SPORTIF V. METHODS .
SPORTIF III was an open - label trial comparing ximelagatran with warfarin for stroke prevention in atrial fibrillation .
We found that lower international normalized ratio variability , a higher proportion of prevalent warfarin use , lower systolic blood pressure , high - density lipoprotein , and a greater proportion of statin use among patients in SPORTIF V collectively conferred a lower risk of stroke .
The rate of stroke among warfarin - treated patients in SPORTIF V was approximately half that of patients enrolled in SPORTIF III ( 1.16%/year versus 2.30%/year ) .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
Independent risk factors for stroke on warfarin included prior stroke / transient ischemic attack , coronary artery disease , international normalized ratio , weight , and study .
All Topics